McKesson price target raised to $825 from $800 at Evercore ISI

Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on McKesson (MCK) to $825 from $800 and keeps an Outperform rating on the shares after the company’s investor day, which provided “a fresh perspective on its strategic priorities” and featured FY26 guidance that has been updated with higher EPS and AOI growth expectations. McKesson is “strategically positioning itself for sustained growth by leveraging its strengths in oncology and biopharma,” while optimizing its portfolio, the analyst tells investors.